Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-AEGIS: MAGIC/FLOT vs CROSS in Esophageal Adenocarcinoma
NCT01726452Phase 3Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2013
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 5
01
Overview
A Phase 3 trial of epirubicin, Cisplatin micelle injection (HA132), oxaliplatin, fluorouracil, capecitabine in esophageal adenocarcinoma (EAC), adenocarcinoma of the gastroesophageal junction, sponsored by Cancer Trials Ireland. Started Jan 2013; status: completed.
02
Drugs
epirubicinCisplatin micelle injection (HA132)oxaliplatinfluorouracilcapecitabine
03
Conditions
esophageal adenocarcinoma (EAC)adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT01726452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726452.